A method for preparing a lindera alkyl sesquiterpene geraniol hybrid and its application

By extracting and isolating the alkyl sesquiterpene and geraniol phenylfuranone hybrid from Lindera strychnifolia, the problem of insufficient research on structurally complex components in Lindera strychnifolia has been solved, providing a safe and effective neuroprotective drug for the treatment of neurodegenerative diseases such as Alzheimer's disease.

CN123106601APending Publication Date: 2026-11-17SHANGHAI UNIV OF MEDICINE & HEALTH SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611312253.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-27
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies have limited research on the structurally complex heteroterpenoid components in Lindera strychnifolia and the development of their pharmacological activities. Furthermore, existing nonsteroidal anti-inflammatory drugs have significant side effects when treating neurodegenerative diseases, making it difficult to find safe and effective neuroprotective drugs.

Method used

The sesquiterpene arabinoyl arabinoyl benzoyl phenylfuranone heteropolymer was extracted and isolated from the traditional Chinese medicine Lindera strychnifolia. The compound was obtained through a multi-step extraction and purification method and then applied to the preparation of pharmaceutical compositions.

Benefits of technology

This compound significantly inhibits microglial cell activation and blocks the release of neurotoxic mediators without cytotoxicity, exhibiting anti-neuroinflammatory and neuroprotective effects, and is suitable for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106601A_ABST
    Figure CN123106601A_ABST
Patent Text Reader

Abstract

This invention relates to a method for preparing a lindera alkyl sesquiterpene and its application, belonging to the fields of natural product chemistry and pharmaceutical technology. This invention extracts and isolates a novel lindera alkyl sesquiterpene and its geraniol hybrid from the traditional Chinese medicine Lindera strychnifolia. In vitro activity experiments show that this compound, at a safe concentration without cytotoxicity, can significantly inhibit lipopolysaccharide (LPS)-induced microglial cell activation and, in a concentration-dependent manner, block the release of neurotoxic inflammatory mediators such as nitric oxide (NO), thereby exhibiting excellent anti-neuroinflammatory and neuroprotective effects. This demonstrates that the compound of this invention possesses in vitro neuroprotective activity, providing a candidate compound for the development of new drugs for neuroprotection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a method for preparing a sesquiterpene hybrid of lindera alkyl sesquiterpene and geraniol, and its application, belonging to the fields of natural product chemistry and pharmaceutical technology. Background Technology

[0002] Lindera aggregata (Sims) Kosterm, the dried root of a plant in the genus Lindera (family Lauraceae), is a traditional and precious Chinese medicinal herb, first recorded in the *Compendium of Materia Medica*. It possesses significant effects in promoting qi circulation, relieving pain, warming the kidneys, and dispelling cold. Modern pharmacological studies have shown that Lindera aggregata contains abundant sesquiterpenes, alkaloids, and volatile oils, exhibiting various biological activities such as anti-inflammatory, analgesic, and visceral protection. However, for a long time, the discovery of active ingredients in Lindera aggregata has focused primarily on common structural types, while research and pharmacological activity development of its complex heteroterpenoid components remain very limited.

[0003] With the increasing aging of modern society, the incidence of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) is rising year by year, becoming a major threat to human health. Modern medical research has confirmed that chronic neuroinflammatory responses in the central nervous system are a key pathological feature leading to the occurrence and development of neurodegenerative diseases. In this pathological process, microglia, the immune effector cells resident in the brain, play a crucial "double-edged sword" role. When stimulated by pathogens (such as lipopolysaccharide LPS) or pathological proteins, microglia are overactivated, bursting out large amounts of nitric oxide (NO), prostaglandin E2 (PGE2), and inflammatory cytokines. Among them, the excessive release of NO has strong neurotoxicity, which can directly lead to damage and apoptosis of host cells and adjacent neurons, triggering a cascade amplification of the inflammatory response, ultimately leading to cognitive loss and neuronal death. Therefore, finding drugs that can safely and effectively inhibit microglial cell activation and thus block the release of neurotoxic mediators such as NO is an important breakthrough direction for the international development of new drugs to prevent and treat neurodegenerative diseases such as Alzheimer's disease.

[0004] While nonsteroidal anti-inflammatory drugs (NSAIDs) currently used in clinical practice can alleviate some inflammatory symptoms to a certain extent, long-term use is often accompanied by serious side effects such as gastrointestinal mucosal damage and liver and kidney dysfunction, making them unsuitable for long-term chronic disease management in patients with neurodegenerative diseases.

[0005] Based on this, from the perspective of microglial cell activation and chronic neuroinflammation, exploring novel, safe, and effective natural small molecule drugs from the traditional Chinese medicine Lindera strychnifolia is of great practical significance and clinical value for enriching the modern scientific connotation of Lindera strychnifolia and developing innovative neuroprotective drugs with independent intellectual property rights. Summary of the Invention

[0006] Purpose of the invention: In view of the above-mentioned problems in related technologies, in order to overcome the deficiencies in the existing technology, the present invention provides a method for preparing a sesquiterpene-type lindera alkyl benzofuranone hybrid compound and its application. It is extracted and isolated from the traditional Chinese medicine Lindera strychnifolia. This compound has in vitro neuroprotective activity and provides a candidate compound for the development of new drugs for neuroprotection.

[0007] Technical solution: To achieve the above objectives, the technical solution adopted by this invention is as follows: On one hand, the present invention provides a lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid, wherein the lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid has the following structural formula (I):

[0008] (I).

[0009] On the other hand, the present invention also provides a method for preparing a sesquiterpene-type lindera alkyl benzoyl phenylfuranone hybrid compound, which is a method for extracting and separating the above-mentioned compound from the traditional Chinese medicine Lindera strychnifolia, and includes the following steps: Step 1) After air drying and pulverizing, Lindera root powder is obtained; Step 2) The Lindera root powder is subjected to reflux extraction, and the obtained extract is concentrated under reduced pressure to obtain the total extract; Step 3) The total extract is suspended and dispersed in water, and extracted sequentially with petroleum ether, ethyl acetate and n-butanol to obtain extracts of each fraction; Step 4) The petroleum ether extract obtained in Step 3) is separated and purified to obtain a lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid.

[0010] Preferably, in one embodiment of the present invention, in step 1), the particle size of the Lindera root powder is such that it passes through a 10-mesh sieve.

[0011] Preferably, in one embodiment of the present invention, in step 2), the solvent used for the reflux extraction is 80% ethanol.

[0012] Preferably, in one embodiment of the present invention, in step 2), the reflux extraction is performed a total of 4 times.

[0013] Preferably, in one embodiment of the present invention, in step 3), the boiling point range of the petroleum ether is 60°C-90°C.

[0014] Preferably, in one embodiment of the present invention, in step 3), equal volumes of petroleum ether, ethyl acetate and n-butanol are used for extraction in sequence to obtain petroleum ether fraction extract, ethyl acetate fraction extract and n-butanol fraction extract, respectively.

[0015] Preferably, in one embodiment of the present invention, in step 3), petroleum ether, ethyl acetate and n-butanol are each extracted 4 times.

[0016] Preferably, in one embodiment of the present invention, in step 4), the separation and purification includes: Step 4.1) The petroleum ether fraction extract was subjected to silica gel column chromatography and gradient elution was performed using a petroleum ether-ethyl acetate system to obtain fraction Fr.6; Step 4.2) The fraction Fr.6 was subjected to first RP C-18 reverse phase column chromatography with gradient elution using a methanol-water system to obtain subfraction Fr.6-4; Step 4.3) The subfraction Fr.6-4 was subjected to a second RP C-8 reversed-phase column chromatography and eluted with an acetonitrile-water system; finally, it was purified by high performance liquid chromatography and eluted with a methanol-water system to obtain the lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid.

[0017] Preferably, in one embodiment of the present invention, in step 4.1), the petroleum ether-ethyl acetate system is a petroleum ether-ethyl acetate system with a volume ratio of 100:0-0:100.

[0018] Preferably, in one embodiment of the present invention, in step 4.2), the methanol-water system is a methanol-water system with a volume ratio of 30:70-100:0.

[0019] Preferably, in one embodiment of the present invention, in step 4.3), the elution system used for the second RP C-8 reversed-phase column chromatography is an acetonitrile-water system with a volume ratio of 65:35; the elution system used for the high-performance liquid chromatography semi-preparative purification is a methanol-water system with a volume ratio of 55:45.

[0020] On the other hand, the present invention also provides a pharmaceutical composition comprising the above-described lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid.

[0021] Preferably, in one embodiment of the invention, the pharmaceutical composition further includes a pharmaceutically acceptable carrier or excipient, formulated into an oral or non-oral dosage form. For example, it may be granulated and compressed with starch or microcrystalline cellulose.

[0022] On the other hand, the present invention also provides the use of the above-described lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid or the above-described pharmaceutical composition in the preparation of drugs for the prevention and / or treatment of neuroinflammatory diseases.

[0023] Preferably, in one embodiment of the invention, the neuroinflammatory condition includes neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease.

[0024] Beneficial Effects: This invention extracted a sesquiterpene-type lindermide compound from Lindera strychnifolia. In vitro activity experiments showed that this compound, at a safe concentration without cytotoxicity, significantly inhibited lipopolysaccharide (LPS)-induced microglial activation and, in a concentration-dependent manner, blocked the release of neurotoxic inflammatory mediators such as NO, thereby exhibiting excellent anti-neuroinflammatory and neuroprotective effects. This indicates that the compound can be used to prepare drugs for the prevention and / or treatment of neuroinflammatory diseases, providing a novel direction and candidate drug for the clinical development and research of new drugs for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease. Attached Figure Description

[0025] To more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0026] Figure 1 High-resolution mass spectrometry (HRESIMS) of the compound in Example 1 of this invention. Figure 2 The proton nuclear magnetic resonance spectrum of the compound in Example 1 of this invention (NMR spectrum) 1 (H NMR spectrum); Figure 3 The carbon NMR spectrum of the compound in Example 1 of this invention ( 13 (C NMR and DEPT-135 spectra). Figure 4 The hydrogen-hydrogen homonuclear chemical shift correlation spectrum of the compound in Example 1 of this invention ( 1 H- 1 H COSY spectrum); Figure 5This is the heteronuclear single quantum correlation spectrum (HSQC spectrum) of the compound in Example 1 of the present invention. Figure 6 This is the heteronuclear multibond correlation spectrum (HMBC spectrum) of the compound in Example 1 of this invention. Figure 7 This is the two-dimensional nuclear Overhauser effect spectrum (NOESY spectrum) of the compound in Example 1 of this invention. Figure 8 The structural formula of the compound in Example 1 of this invention is shown below; Figure 9 This is the concentration-effect curve of the inhibitory effect of the present invention on NO generation in Example 1. Detailed Implementation

[0027] This invention provides a method for preparing a Linderahybridin A heteropolymer (Linderahybridin A), the compound having the following structural formula:

[0028] (I) In one specific embodiment of the present invention, a method for extracting a Linderahybridin A heteropolymer (Linderahybridin A) having the structure of formula (Ⅰ) from Linderah root includes the following steps: Step 1): Obtain Lindera root powder, wherein the powder is coarse Lindera root powder after air drying and crushing; Step 2): The Lindera root powder was subjected to reflux extraction using 80% ethanol as the extraction solvent. The extraction was performed four times. The extracts were combined and concentrated under reduced pressure to obtain the total extract. Step 3): The total extract obtained in Step 2) is suspended and dispersed in water, and then extracted sequentially with equal volumes of petroleum ether (boiling point 60℃-90℃), ethyl acetate and n-butanol. After the solvent is recovered under reduced pressure, the petroleum ether fraction extract, ethyl acetate fraction extract and n-butanol fraction extract are obtained respectively. Step 4): The petroleum ether extract obtained in Step 3) is separated and purified. Specifically, the extract is first subjected to silica gel column chromatography with gradient elution using a petroleum ether-ethyl acetate system (ethyl acetate volume percentage concentration is 0-100%). Based on thin-layer chromatography analysis, six fractions (Fr.1-Fr.6) are collected. Fraction Fr.6 (12.5 g) is subjected to RPC-18 reversed-phase column chromatography with gradient elution using a methanol-water system (methanol to water volume ratio is 30:70 to 100:0). Six subfractions (Fr.6-1-Fr.6-6) are collected. Subfraction Fr.6-4 is subjected to RPC-8 reversed-phase column chromatography with acetonitrile-water system (65:35) for elution. Finally, it is purified by high-performance liquid chromatography with methanol-water system (55:45) to obtain Lindera triterpenoid A (8.0 mg) with the structure of formula (Ⅰ).

[0029] During the research of natural medicines, the inventors of this invention unexpectedly isolated a new lindera alkyl sesquiterpene and geraniol phenylfuranone heteropolymer from the dried root of Lindera aggregata (Sims) Kosterm., a plant of the genus Lindera in the family Lauraceae, namely the compound with the structure of the above formula (I) (Lindera sesquiterpene A).

[0030] The compound with the formula (Ⅰ) structure isolated from Linderah root has never been reported in the literature. After structural identification and analysis, the inventor named it Linderahybridin A. In the process of further pharmacodynamic screening, it was found that the compound has significant protective and therapeutic effects on the prevention and / or treatment of neuroinflammatory and neurodegenerative diseases (such as Alzheimer's disease), and has the potential for clinical application as a novel anti-neuroinflammatory and neuroprotective drug.

[0031] The present invention will be further illustrated by the following embodiments, but the present invention is not limited to these specific embodiments. The present invention can be better understood from the following embodiments. However, those skilled in the art will readily understand that the specific material ratios, process conditions, and results described in the embodiments are for illustrative purposes only and should not, and will not, limit the present invention as described in detail in the claims.

[0032] The instruments, equipment, and experimental materials used in the embodiments of this invention are as follows.

[0033] Magnetic Resonance Imaging Spectrometer: Brucker Avance DRX-600; Mass spectrometer: Agilent 6230 Accurate Mass Q-TOF UHPLC / MS liquid chromatography-mass spectrometry system; Polarimeter: Autopol VI 90079; High performance liquid chromatograph: Agilent 1100, quaternary pump, autosampler and DAD detector; Column chromatography silica gel (200-300, 300-400 mesh) is a product of Qingdao Marine Chemical Plant; Thin-layer chromatography reagents: 10% H2SO4-ethanol solution, 95% ethanol, petroleum ether, ethyl acetate, dichloromethane, acetone, methanol, etc. are all analytical grade solvents (Shanghai Chemical Reagent Co., Ltd., China National Pharmaceutical Group), acetonitrile (chromatographic grade, Merck).

[0034] Plant source The root of Lindera aggregata (medicinal raw material) was collected in July 2025 from Taizhou City, Zhejiang Province. It was identified by Professor Zhou Xiujia of Shanghai University of Traditional Chinese Medicine as the dried root of Lindera aggregata (Sims) Kosterm., a plant of the genus Lindera in the family Lauraceae. The specimen is stored in the Central Laboratory of the South Campus of the Sixth People's Hospital Affiliated to Shanghai Jiaotong University (Specimen No. 20250720WY).

[0035] Example 1: Preparation of Lindera triterpenoid A Step 1): First, take 8.5 kg (dry weight) of Lindera root, let it dry naturally in the air, then crush it to obtain coarse Lindera root powder. Pass it through a 10-mesh sieve to obtain Lindera root powder. Step 2): The Lindera root powder obtained in Step 1) is subjected to reflux extraction. Specifically, it is extracted four times by reflux extraction with 80% ethanol. The extracts are combined and concentrated under reduced pressure to obtain the total extract. Step 3): The total extract obtained in Step 2) is suspended and dispersed in 4 liters of water, and then extracted sequentially with equal volumes (4 liters) of petroleum ether (boiling point range of 60℃-90℃), ethyl acetate and n-butanol. Each organic solvent is extracted 4 times. After the solvent is recovered under reduced pressure, the extracts of each extraction fraction are obtained. The mass of the petroleum ether fraction extract is 73.0 g. Step 4): The petroleum ether fraction extract (73.0 g) obtained in Step 3) is separated and purified, specifically including: Step 4.1) First, silica gel column chromatography was performed using a petroleum ether-ethyl acetate system with gradient elution (volume ratio of petroleum ether to ethyl acetate was 100:0 to 0:100). Based on thin-layer chromatography analysis, six components (Fr.1-Fr.6) were collected. It should be noted that in this step, gradient elution means that the mobile phase is eluted from 0% ethyl acetate to 100% ethyl acetate to achieve preliminary separation of the components, and then isocratic separation is used for subsequent separation.

[0036] Step 4.2) The fraction Fr.6 (12.5 g) was subjected to RP C-18 reversed-phase column chromatography with gradient elution using a methanol-water system (methanol to water volume ratio of 30:70 to 100:0), and the fractions were collected to obtain 6 subfractions (Fr.6-1-Fr.6-6). It should be noted that in this step, gradient elution means that the mobile phase is eluted from 30% methanol to 100% methanol in a linear manner to achieve the initial separation of the fractions, and then isocratic separation is used for subsequent separation.

[0037] Step 4.3) The subfraction Fr.6-4 was subjected to RP C-8 reversed-phase column chromatography, eluted with an acetonitrile-water system (65:35, v / v); and finally purified by high performance liquid chromatography (HPLC) using a JASCO PU-4087, eluted with a methanol-water system (55:45, v / v) at a flow rate of 3 mL / min. The target peak was collected and evaporated to dryness under reduced pressure to obtain a purified amorphous yellow powder (8.0 mg).

[0038] Example 2: Structural Identification of Compounds The amorphous yellow powder obtained in Example 1 was analyzed by high-resolution electrospray mass spectrometry (HRESIMS), and the results are as follows: Figure 1 As shown in the figure, a pseudomolecular ion peak (calculated value 559.3113) was observed at m / z 559.3073, thus confirming its molecular formula as C. 35 H 42 O6 has an unsaturation degree of 15.

[0039] A series of nuclear magnetic resonance (NMR) spectroscopy analyses were then performed, and the results are attached. Figure 2-7 As shown in the figure, by comparing its NMR data with those of known compounds, it can be seen that this compound contains a lindenenol structural unit and a geranylidene furanone structural unit. The figure also shows a distinctive double-bonded carbon signal, with chemical shifts at C-12' ​​(δ). C 168.6) and C-7 (δ C At position 100.3), NMR data combined with molecular formula information indicate that the linderol structural unit in this compound may be linked to geranylide via a double bond. This structural derivation was further verified by two-dimensional NMR experiments.

[0040] like Figure 6As shown, in the HMBC spectrum, long-range correlation signals between the methyl proton signal CH3-13 and C-7', C-11', and C-12', as well as long-range correlation signals between the benzene ring hydrogen H-4 and the carbon signal C-7, can be clearly observed, thus confirming the aforementioned connection mode. Furthermore, in Figure 2 shown 1 In the H NMR spectrum, located at δ H The H3-14' methyl proton signal at 0.54 is relative to the δ of known similar compounds. H The significant shift to higher fields (shielding effect) at 0.87 indicates that the methyl group at the H3-14' position and the ethoxy group at the 8' position in this compound are in an anti-trans configuration.

[0041] Subsequently, the NOESY spectrum correlation signal ( Figure 7 Analysis shows that, for example Figure 8 As shown, the sesquiterpene unit fragment in this compound has the exact same relative configuration as lindenenol.

[0042] Through the combined identification process of three-dimensional and two-dimensional nuclear magnetic resonance, the skeletal structure of the yellow powder compound was finally confirmed to be: a novel hybrid compound formed by a double bond bridge coupling a sesquiterpene unit to a geranyl benzofuranone unit. The inventors formally named it Linderahybridin A, with the structural formula as follows: Figure 8 And as shown in the following formula (Ⅰ):

[0043] (I).

[0044] The physicochemical data of this compound are as follows: Specific rotation: [α]22.5 D -197.1 (c 0.3, MeOH); Ultraviolet spectrum: (MeOH): λ max (log ε) 206 (4.85), 232 (4.03), 280 (4.06), 350 (4.08); Infrared spectrum: ν max 3392, 2971, 2925, 1735, 1650, 1441, 1273, 1122, 982, 859cm -1 .

[0045] The NMR data for this compound are shown in Table 1.

[0046] Table 1. Proton and carbon spectral data of the compounds (deuterated chloroform, 1 H NMR 600 MHz;13 C NMR 150 MHz)

[0047] Example 3: In vitro cell viability verification To further verify the neuroprotective activity of this compound, we evaluated its inhibitory effect on lipopolysaccharide-induced NO production in mouse microglia. The specific implementation method is as follows.

[0048] Experimental materials and cell lines: mouse microglial cell line (murine BV-2 microglial cells, BV-2 cells).

[0049] Reagents: Lipopolysaccharide (LPS, Sigma); DMEM high-glucose medium, fetal bovine serum (FBS, Gibco); CCK-8 cell viability assay kit; NO assay kit (Griess method).

[0050] Experimental steps: (a) Cell culture and plating: BV-2 cells were maintained in DMEM medium containing 10% fetal bovine serum and passaged in a 37°C, 5% CO2 incubator. Before the experiment, BV-2 cells in the logarithmic growth phase were cultured at 1 × 10⁻⁶ cells / year. 5 The cells were seeded at a density of 100 µL / mL in 96-well plates and incubated adherently for 24 hours.

[0051] (b) Experimental grouping and drug administration: The experiment was divided into four groups, with six replicates in each group: Blank control group: Only an equal volume of culture medium was added; LPS model group: activation was stimulated by adding culture medium containing LPS (final concentration of 1 µg / mL); Positive control group: The positive control drug (minocycline) was added first, and LPS (1 µg / mL) was added 1 hour later. Lindera triterpenoid A administration group: Lindera triterpenoid A of different concentration gradients (5, 10, 20, 40 µM) was added first, and after 1 hour of pretreatment, LPS (1 µg / mL) was added for co-incubation.

[0052] (c) NO emission determination: After co-incubating the drug with LPS for 24 hours, carefully aspirate 50 µL of cell supernatant from each group and place it in a brand new 96-well plate. Strictly follow the Griess kit instructions, adding Griess Reagent I and II sequentially, mixing wells with a micropipette, and measuring the absorbance (OD value) of each well at 540 nm using a microplate reader. The concentration of NO in the supernatant is then calculated using a standard curve.

[0053] (d) Cytotoxicity evaluation (CCK-8 assay): To rule out false positives caused by drug-induced cell death due to NO reduction, 100 µL of fresh culture medium containing 10% CCK-8 solution was added to each well of the original 96-well plate after aspirating the supernatant, and the plates were incubated for another 2 hours. Absorbance was measured at 450 nm using a microplate reader to calculate cell viability. NO inhibition rate was calculated based on NO release levels after treatment with different concentrations of Linderae Radix A. The results are shown in Table 2.

[0054] A concentration-response curve was plotted with the logarithm of drug concentration on the x-axis and the NO inhibition rate on the y-axis, and fitted using a nonlinear regression method. The drug concentration required to reduce LPS-induced NO release by 50%, i.e., the half-maximal inhibitory concentration (IC50), was calculated based on the fitted curve. 50 Each experiment should be independently repeated at least 3 times, IC50 50 Results are expressed as mean ± standard deviation.

[0055] Table 2. Cell viability and NO inhibition rate of each experimental group

[0056] Compared with the LPS model control group, "*" indicates P < 0.05; "**" indicates P < 0.01. As shown in Table 2, at a safe concentration of 5-40 µM with no cytotoxicity, Lindera triterpenoid A can significantly and in a concentration-dependent manner inhibit LPS-induced NO release from BV-2 microglia.

[0057] according to Figure 9 The fitted curves shown indicate that the half-maximal inhibitory concentration (IC50) is 12.45 ± 1.57 µM, demonstrating potent anti-neuroinflammatory and neuroprotective activity.

[0058] Since the core pathology of AD / PD is chronic activation of microglia leading to NO toxicity and neuronal death, the compounds of this invention block this pathway in vitro, and therefore can be used to prepare AD / PD drugs. This demonstrates that the compounds of this invention can exert excellent anti-neuroinflammatory and neuroprotective effects, and can be applied to the preparation of drugs for the prevention and / or treatment of neuroinflammatory diseases. This provides a new direction and candidate drugs for the development and research of new drugs for the clinical prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.

[0059] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A lindera alkyl sesquiterpene geraniol hybrid compound, characterized in that, The lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid has the following structural formula (Ⅰ).

2. The method for preparing the lindera alkyl sesquiterpene and geraniol hybrid compound according to claim 1, characterized in that, Includes the following steps: Step 1) After air drying and pulverizing, Lindera root powder is obtained; Step 2) The Lindera root powder is subjected to reflux extraction, and the obtained extract is concentrated under reduced pressure to obtain the total extract; Step 3) The total extract is suspended and dispersed in water, and extracted sequentially with petroleum ether, ethyl acetate and n-butanol to obtain extracts of each fraction; Step 4) The petroleum ether extract obtained in Step 3) is separated and purified to obtain a sesquiterpene-type lindera benzoylbenzene-furanone hybrid.

3. The method as described in claim 2, characterized in that, In step 2), the solvent used for the reflux extraction is 80% ethanol; and / or In step 2), the reflux extraction is performed a total of 4 times.

4. The method as described in claim 2, characterized in that, In step 3), the boiling point range of the petroleum ether is 60°C-90°C; and / or In step 3), extraction is performed sequentially using equal volumes of petroleum ether, ethyl acetate, and n-butanol; and / or In step 3), petroleum ether, ethyl acetate and n-butanol are each extracted 4 times.

5. The method as described in claim 2, characterized in that, In step 4), the separation and purification includes: Step 4.1) The petroleum ether fraction extract was subjected to silica gel column chromatography and gradient elution was performed using a petroleum ether-ethyl acetate system to obtain fraction Fr.6; Step 4.2) The fraction Fr.6 was subjected to first RP C-18 reverse phase column chromatography with gradient elution using a methanol-water system to obtain subfraction Fr.6-4; Step 4.3) The subfraction Fr.6-4 was subjected to a second RP C-8 reversed-phase column chromatography and eluted with an acetonitrile-water system; finally, it was purified by high performance liquid chromatography and eluted with a methanol-water system to obtain the lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid.

6. The method as described in claim 5, characterized in that, In step 4.1), the petroleum ether-ethyl acetate system is a petroleum ether-ethyl acetate system with a volume ratio of 100:0-0:100; In step 4.2), the methanol-water system is a methanol-water system with a volume ratio of 30:70-100:

0.

7. The method as described in claim 5, characterized in that, In step 4.3), the elution system used for the second RP C-8 reversed-phase column chromatography is an acetonitrile-water system with a volume ratio of 65:35; the elution system used for the high-performance liquid chromatography semi-preparative purification is a methanol-water system with a volume ratio of 55:

45.

8. A pharmaceutical composition, characterized in that, Including the lindera alkyl sesquiterpene and geraniol phenylfuranone hybrid as described in claim 1.

9. The use of the lindera alkyl sesquiterpene and geraniol hybrid as described in claim 1 or the pharmaceutical composition as described in claim 8 in the preparation of a drug for the prevention and / or treatment of neuroinflammatory diseases.

10. The application as described in claim 9, characterized in that, The neuroinflammatory condition includes neurodegenerative diseases, including Alzheimer's disease or Parkinson's disease.